Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Halozyme Therapeutics’ Positive Results for Patients with Chronic Inflammatory Demyelinating Polyneuropathy

July 21, 2023 0

The way drugs are being delivered into patients’ bodies have become more than ever considered important …

Treating Cancers Resistant to ALL Drugs a Priority for Researchers. See What Merck and Kintara Have Done

July 20, 2023 0

Merck and Kintara in the NEWS Treating cancers that have no treatments should be a priority …

Treatments for Untreatable Diseases

July 16, 2023 0

Prohost Letter #456 Treatments for Untreatable Diseases The revolution in biotechnology is not meant to offer …

The U.S. FDA Approved BioMarin’s ROCTAVIANTM, the First and Only Gene Therapy for Adults with Severe Hemophilia A in the US

July 6, 2023 0

BioMarin Pharmaceutical US FDA Approval for ROCTAVIAN On June 30, 2023, BioMarin Pharmaceutical (BMRN) announced that …

The U.S.FDA Granted CellTrans Inc., Approval of its Product Lantidra for the Treatment of Type 1 Diabetes

June 30, 2023 0

CellTrans Inc FDA Approval for Lantidra for Type 1 Diabetes The U.S. Food and Drug Administration …

The U.S. FDA Approved BioMarin Pharmaceutical’s ROCTAVIAN, the First and Only Gene Therapy for Adults with Severe Hemophilia A

June 30, 2023 0

BioMarin Pharmaceutical US FDA Approved ROCTAVIAN BioMarin Pharmaceutical (BMRN) announced that the U.S. FDA approved ROCTAVIAN …

Bayer & BlueRock Therapeutics: A First Neuronal Stem Cell Therapy to Show Positive Results in Phase I Clinical Study for Parkinson’s Disease

June 29, 2023 0

Bayer and BlueRock Therapeutics Berlin, Germany and Cambridge, M.A., U.S.A., June 28, 2023 – Bayer AG (BAYRY) …

Prohost Letter #455

June 28, 2023 0

Prohost Letter #455 Introduction Our Prohost Letter disappeared for six months. Several reasons dictated our decision …

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in Netherlands to Start Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca Imfinzi for Treatment of Pancreatic Cancer

June 27, 2023 0

AIM ImmunoTech Announcement AIM ImmunoTech (AIM) - an immuno-pharma company focused on the research and development …

Celmatix Inc: Revolutionizing Fertility Treatments

June 27, 2023 0

Celmatix Inc. Celmatix Inc., announced the identification of promising early leads in its latest drug program, …

Arbutus Biopharma Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial That Includes a PD-1 Monoclonal Antibody Nivolumab

June 21, 2023 0

Arbutus Biopharma Announcement Today, June 21, 2023, Arbutus Biopharma (ABUS) announced that the first patient has …

Vera Therapeutics Announces Positive Week 36 Safety and Efficacy Results in Phase 2b Clinical Trial of Atacicept in IgA Nephropathy

June 20, 2023 0

Vera Therapeutics Vera Therapeutics (VERA) announced that Phase 2b ORIGIN clinical trial of atacicept for IgA …

At 2:30 PM Today the Chairman of the Federal Reserve will Reveal the Decision About Interest Rates. See Also: Good News from Gilead

June 14, 2023 0

Today at 2.30... Today at 2.30, the Federal Reserve Chairman Jerome Powell will speak to the …

Why the UT Southwestern Medical Center is Enrolling Cancer Patients in Phase III TIGeR-PaC Clinical Trial from RenovoRx

June 1, 2023 0

UT Southwestern Medical Center and RenovoRx RenovoRx Inc (RNXT) announced that the University of Texas (UT) …

Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS

May 30, 2023 0

Amylyx Pharmaceuticals Amylyx Pharmaceuticals (AMLX) announced an update on the ongoing review of its Marketing Authorization …

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619 at ASCO 2023

May 26, 2023 0

Inside the Revolution In the Treatments of Untreatable Diseases We are now living a great revolution …

Our Eyes Are on Reata Pharmaceuticals Today

May 25, 2023 0

Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals (RETA) announced a setback of its chronic kidney disease …

Intercept Pharmaceuticals Stock is Halted Today as the FDA Advisory Committee is Reviewing Obeticholic Acid as a Treatment of NASH Precirrhotic Fibrosis

May 19, 2023 0

Intercept Pharmaceuticals Intercept Pharmaceuticals Inc (ICPT) is a biopharmaceutical company focused on the development and commercialization …

Bio-Techne ExoDx Prostate Test is More Accurate in High- and Low-Risk Patients Compared to Standard of Care

May 18, 2023 0

Prostate Cancer Prostate cancer is the most common type of cancer found in men, accounting for …

Celldex Therapeutics Presented Positive Preclinical Data from its TSLP/SCF Bispecific Antibody Program CDX-622 at AAI

May 15, 2023 0

Celldex Therapeutics Announcement Celldex Therapeutics (CLDX) announced today preclinical data from its CDX-622 bispecific antibody with …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Halozyme Therapeutics’ Positive Results for Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Treating Cancers Resistant to ALL Drugs a Priority for Researchers. See What Merck and Kintara Have Done

Treatments for Untreatable Diseases

The U.S. FDA Approved BioMarin’s ROCTAVIANTM, the First and Only Gene Therapy for Adults with Severe Hemophilia A in the US

The U.S.FDA Granted CellTrans Inc., Approval of its Product Lantidra for the Treatment of Type 1 Diabetes

The U.S. FDA Approved BioMarin Pharmaceutical’s ROCTAVIAN, the First and Only Gene Therapy for Adults with Severe Hemophilia A

Bayer & BlueRock Therapeutics: A First Neuronal Stem Cell Therapy to Show Positive Results in Phase I Clinical Study for Parkinson’s Disease

Prohost Letter #455

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in Netherlands to Start Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca Imfinzi for Treatment of Pancreatic Cancer

Celmatix Inc: Revolutionizing Fertility Treatments

Arbutus Biopharma Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial That Includes a PD-1 Monoclonal Antibody Nivolumab

Vera Therapeutics Announces Positive Week 36 Safety and Efficacy Results in Phase 2b Clinical Trial of Atacicept in IgA Nephropathy

At 2:30 PM Today the Chairman of the Federal Reserve will Reveal the Decision About Interest Rates. See Also: Good News from Gilead

Why the UT Southwestern Medical Center is Enrolling Cancer Patients in Phase III TIGeR-PaC Clinical Trial from RenovoRx

Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619 at ASCO 2023

Our Eyes Are on Reata Pharmaceuticals Today

Intercept Pharmaceuticals Stock is Halted Today as the FDA Advisory Committee is Reviewing Obeticholic Acid as a Treatment of NASH Precirrhotic Fibrosis

Bio-Techne ExoDx Prostate Test is More Accurate in High- and Low-Risk Patients Compared to Standard of Care

Celldex Therapeutics Presented Positive Preclinical Data from its TSLP/SCF Bispecific Antibody Program CDX-622 at AAI